Ichnos Glenmark Innovation (IGI) has announced a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to evaluate IGI’s selective, orally active Casitas B-lineage lymphoma b (Cbl-b) inhibitor GRC-65327.